The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Plk3 Functionally Links DNA Damage to Cell Cycle Arrest and Apoptosis at Least in Part via the p53 Pathway
Open accessAbstract
Polo-like kinase 3 (Plk3, previously termed Prk) contributes to regulation of M phase of the cell cycle (Ouyang, B., Pan, H., Lu, L., Li, J., Stambrook, P., Li, B., and Dai, W. (1997) J. Biol. Chem. 272, 28646-28651). Plk3 physically interacts with Cdc25C and phosphorylates this protein phosphatase predominantly on serine 216 (Ouyang, B., Li, W., Pan, H., Meadows, J., Hoffmann, I., and Dai, W. (1999) Oncogene 18, 6029-6036), suggesting that the role of Plk3 in mitosis is mediated, at least in part, through direct regulation of Cdc25C. Here we show that ectopic expression of a kinase-active Plk3 (Plk3-A) induced apoptosis. In response to DNA damage, the kinase activity of Plk3 was rapidly increased in an ATM-dependent manner, whereas that of Plk1 was markedly inhibited. Recombinant Plk3 phosphorylated in vitro a glutathione S-transferase fusion protein containing p53, but not glutathione S-transferase alone. Recombinant Plk1 also phosphorylated p53 but on residues that differed from those targeted by Plk3. Co-immunoprecipitation and pull-down assays demonstrated that Plk3 physically interacted with p53 and that this interaction was enhanced upon DNA damage. In vitro kinase assays followed by immunoblotting showed that serine 20 of p53 was a target of Plk3. Furthermore, expression of a kinase-defective Plk3 mutant (Plk3(K52R)) resulted in significant reduction of p53 phosphorylation on serine 20, which was correlated with a decrease in the expression of p21 and with a concomitant increase in cell proliferation. These results strongly suggest that Plk3 functionally links DNA damage to cell cycle arrest and apoptosis via the p53 pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Peng, C.-Y., Graves, P. R., Thoma, R. S., Wu, Z., Shaw, A. S., & Piwnica-Worms, H. (1997) · Science · doi:10.1126/science.277.5331.1501 · Cited by 1,341
Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms, H., & Elledge, S. J. (1997) · Science · doi:10.1126/science.277.5331.1497 · Cited by 1,320
A role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046
Shieh, S.-Y., Ahn, J., Tamai, K., Taya, Y., & Prives, C. (2000) · Genes & Development · doi:10.1101/gad.14.3.289 · Cited by 972
Chk2/hCds1 functions as a DNA damage checkpoint in G1by stabilizing p53
Chehab, N. H., Malikzay, A., Appel, M., & Halazonetis, T. D. (2000) · Genes & Development · doi:10.1101/gad.14.3.278 · Cited by 805
Control of the DNA damage checkpoint by Chk1 and Rad53 protein kinases through distinct mechanisms
Sanchez, Y., Bachant, J., Wang, H., Hu, F., Liu, D., Tetzlaff, M., & Elledge, S. J. (1999) · Science · doi:10.1126/science.286.5442.1166 · Cited by 536
Cited by
Polo-like kinases and the orchestration of cell division
Barr, F. A., Silljé, H. H. W., & Nigg, E. A. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1401 · Cited by 1,087
Toward Maintaining the Genome: DNA Damage and Replication Checkpoints
Nyberg, K. A., Michelson, R. J., Putnam, C. W., & Weinert, T. A. (2002) · Annual Review of Genetics · doi:10.1146/annurev.genet.36.060402.113540 · Cited by 777
Elia, A. E. H., Rellos, P., Haire, L. F., Chao, J. W., Ivins, F. J., Hoepker, K., Mohammad, D., Cantley, L. C., Smerdon, S. J., & Yaffe, M. B. (2003) · Cell · doi:10.1016/s0092-8674(03)00725-6 · Cited by 760
An atlas of substrate specificities for the human serine/threonine kinome
Johnson, J. L., Yaron, T. M., Huntsman, E. M., Kerelsky, A., Song, J., Regev, A., Lin, T.-Y., Liberatore, K., Cizin, D. M., Cohen, B. M., et al. (2023) · Nature · doi:10.1038/s41586-022-05575-3 · Cited by 728
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy
Strebhardt, K. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3184 · Cited by 653
Polo-like kinases: conservation and divergence in their functions and regulation
Archambault, V., & Glover, D. M. (2009) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2653 · Cited by 604
Shared and separate functions of polo-like kinases and aurora kinases in cancer
Lens, S. M. A., Voest, E. E., & Medema, R. H. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2964 · Cited by 597
Polo-like kinases: structural variations lead to multiple functions
Zitouni, S., Nabais, C., Jana, S. C., Guerrero, A., & Bettencourt-Dias, M. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3819 · Cited by 489
DNA damage checkpoint control in cells exposed to ionizing radiation
Iliakis, G., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 476
DNA damage checkpoints in mammals
Niida, H., & Nakanishi, M. (2006) · Mutagenesis · doi:10.1093/mutage/gei063 · Cited by 432
Polo-like kinases and oncogenesis
Eckerdt, F., Yuan, J., & Strebhardt, K. (2005) · Oncogene · doi:10.1038/sj.onc.1208273 · Cited by 365
Activation of the p53 tumor suppressor protein
Vousden, K. H. (2002) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(02)00035-5 · Cited by 337
Structure and function of Polo-like kinases
Lowery, D. M., Lim, D., & Yaffe, M. B. (2005) · Oncogene · doi:10.1038/sj.onc.1208280 · Cited by 293
From Plk1 to Plk5: Functional evolution of polo-like kinases
de Cárcer, G., Manning, G., & Malumbres, M. (2011) · Cell Cycle · doi:10.4161/cc.10.14.16494 · Cited by 273
Getting in and out of mitosis with Polo-like kinase-1
van Vugt, M. A. T. M., & Medema, R. H. (2005) · Oncogene · doi:10.1038/sj.onc.1208617 · Cited by 271
Multisite protein modification and intramolecular signaling
Yang, X.-J. (2005) · Oncogene · doi:10.1038/sj.onc.1208173 · Cited by 266
Polo-like Kinase 1 (Plk1) Inhibits p53 Function by Physical Interaction and Phosphorylation
Ando, K., Ozaki, T., Yamamoto, H., Furuya, K., Hosoda, M., Hayashi, S., Fukuzawa, M., & Nakagawara, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314182200 · Cited by 264
Targeting Polo-like Kinase in Cancer Therapy
Degenhardt, Y., & Lampkin, T. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1380 · Cited by 262
Ligand stimulation of CD95 induces activation of Plk3 followed by phosphorylation of caspase-8
Helmke, C., Raab, M., Rödel, F., Matthess, Y., Oellerich, T., Mandal, R., Sanhaji, M., Urlaub, H., Rödel, C., Becker, S., et al. (2016) · Cell Research · doi:10.1038/cr.2016.78 · Cited by 44
Stimulation of polo-like kinase 3 mRNA decay by tristetraprolin
Horner, T. J., Lai, W. S., Stumpo, D. J., & Blackshear, P. J. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00982-08 · Cited by 26
Sokolov, M., & Neumann, R. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15010588 · Cited by 23
“PLK3 has been demonstrated to be an important mediator of the cellular responses to genotoxic stresses [66], at least in part through the TP53-p21 pathway [67] and the NF-κB pathway [68].”
BackgroundKim, J., Selvaraji, S., Kang, S. W., Lee, W. T., Chen, C. L.-H., Choi, H., Koo, E. H., Jo, D.-G., Leong Lim, K., Lim, Y.-A., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.04.011 · Cited by 20
The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies
Babagana, M., Kichina, J. V., Slabodkin, H., Johnson, S., Maslov, A., Brown, L., Attwood, K., Nikiforov, M. A., & Kandel, E. S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23123 · Cited by 12
Metadata
- Authors
- Xie, S., Wu, H., Wang, Q., Cogswell, J. P., Husain, I., Conn, C., Stambrook, P., Jhanwar-Uniyal, M., & Dai, W.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-11
- Volume
- 276
- Issue
- 46
- Pages
- 43305-43312
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2079645368
- Cited by
- 227
- References
- 6
- FWCI
- 4.61
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.